Product Information

N-[6,6-dimethyl-5-[(1-methylpiperidin-4-yl)oxomethyl]-1,4-dihydropyrrolo[3,4-c]pyrazol-3-yl]-3-methylbutanamide is a piperidinecarboxamide.

CAS No.	718630-59-2
Product Name	Pha-793887

Heavy Atom Count	26	Rotatable Bond Count	4
Atom Stereo Count	0	Bond Stereo Count	0
HBA	4	HBD	2
TPSA	81.330 Å²	Charge	0
Exact Mass	361.24778	Complexity	686.10
pKa	5.875	XLogP	2.313

Studies related to this compound and its mechanism of action

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.

Cell cycle (Georgetown, Tex.) • Vol. 10, Issue 6 • 2011

PMID: 21368575 DOI: 10.4161/cc.10.6.15075

An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

Cell cycle (Georgetown, Tex.) • Vol. 10, Issue 1 • 2011

PMID: 21200142 DOI: 10.4161/cc.10.1.14445

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.

Molecular cancer therapeutics • Vol. 9, Issue 5 • 2010

PMID: 20423997 DOI: 10.1158/1535-7163.MCT-09-1163

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

Bioorganic & medicinal chemistry • Vol. 18, Issue 5 • 2010

PMID: 20153204 DOI: 10.1016/j.bmc.2010.01.042

Pha-793887

CAS No.	718630-59-2
MDL No.	N/A
MF	C₁₉H₃₁N₅O₂
MW	361.50
InChI Key	HUXYBQXJVXOMKX-UHFFFAOYSA-N

CUSTOM SYNTHESIS

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

N-[6,6-dimethyl-5-[(1-methylpiperidin-4-yl)oxomethyl]-1,4-dihydropyrrolo[3,4-c]pyrazol-3-yl]-3-methylbutanamide is a piperidinecarboxamide.

CAS No.	718630-59-2
Product Name	Pha-793887

Heavy Atom Count	26	Rotatable Bond Count	4
Atom Stereo Count	0	Bond Stereo Count	0
HBA	4	HBD	2
TPSA	81.330 Å²	Charge	0
Exact Mass	361.24778	Complexity	686.10
pKa	5.875	XLogP	2.313

Pha-793887

Pricing & Availability

Product Information

Properties

Pha-793887

Pricing & Availability

Product Information

Properties

Documentation

Pha-793887

Pricing & Availability

Product Information

Properties

Related Articles

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.

An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

Pha-793887

Pricing & Availability

Product Information

Properties

Related Articles

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.

An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

Documentation